07.23.14
Winnipeg, Manitoba, Canada-based IMRIS Inc. has obtained CE mark for integrating the next generation MRI (magnetic resonance imaging) core technology into the Visius surgical theater allowing for sales and marketing in the European Union.
This newest imaging technology, based on the Siemens Aera 1.5T (tesla) and Skyra 3.0T MRI scanners, are designed to deliver better image quality, faster 3-D image acquisition, and improved ease-of-use and workflow during surgical procedures using intraoperative MRI (iMRI). IMRIS received U.S. Food and Drug Administration approval for these advancements in February 2014.
“These high-field intraoperative scanner options will give a hospital’s clinical team state-of-the-art applications and image quality that increase productivity,” said President and CEO Jay D. Miller. “We bring the latest and unequaled imaging technology into the operating room where it can make the most difference - during the surgery. More and more neurosurgical centers are using image guidance with Visius iMRI for an expanding list of conditions and procedures and adjunctive interventions beyond brain tumor resections, such as laser ablation for tumors and epilepsy using stereotactic tools, deep brain stimulation (DBS) and other minimally-invasive techniques that are designed to improve patient outcomes.”
Inside a Visius surgical theater equipped with high-field iMRI, surgeons have on-demand access to real-time data and state-of-the-art imaging during the procedure as the scanner uniquely moves on ceiling-mounted rails. IMRIS also designs and manufactures proprietary intraoperative CTs (computed tomography scans), head fixation devices, imaging coils, and OR (operating room) tables for use in this unique and multifunctional intraoperative environment.
IMRIS provides image guided therapy solutions through its Visius surgical theater, which is a multifunctional surgical environment. The company’s U.S. offices are in Minnetonka, Minn.
This newest imaging technology, based on the Siemens Aera 1.5T (tesla) and Skyra 3.0T MRI scanners, are designed to deliver better image quality, faster 3-D image acquisition, and improved ease-of-use and workflow during surgical procedures using intraoperative MRI (iMRI). IMRIS received U.S. Food and Drug Administration approval for these advancements in February 2014.
“These high-field intraoperative scanner options will give a hospital’s clinical team state-of-the-art applications and image quality that increase productivity,” said President and CEO Jay D. Miller. “We bring the latest and unequaled imaging technology into the operating room where it can make the most difference - during the surgery. More and more neurosurgical centers are using image guidance with Visius iMRI for an expanding list of conditions and procedures and adjunctive interventions beyond brain tumor resections, such as laser ablation for tumors and epilepsy using stereotactic tools, deep brain stimulation (DBS) and other minimally-invasive techniques that are designed to improve patient outcomes.”
Inside a Visius surgical theater equipped with high-field iMRI, surgeons have on-demand access to real-time data and state-of-the-art imaging during the procedure as the scanner uniquely moves on ceiling-mounted rails. IMRIS also designs and manufactures proprietary intraoperative CTs (computed tomography scans), head fixation devices, imaging coils, and OR (operating room) tables for use in this unique and multifunctional intraoperative environment.
IMRIS provides image guided therapy solutions through its Visius surgical theater, which is a multifunctional surgical environment. The company’s U.S. offices are in Minnetonka, Minn.